Sarep­ta to col­lab­o­rate with Genethon on DMD gene ther­a­py; Chi­nese in­vestors pull back on Pluris­tem in­vest­ment

→ Cam­bridge, MA-based Sarep­ta $SRPT is dou­bling down on new work fo­cused on de­vel­op­ing a gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy. The biotech inked a deal to col­lab­o­rate with the non­prof­it Genethon, which has been work­ing on an­i­mal mod­els of the dis­ease. “Our agree­ment with Genethon strength­ens our on­go­ing com­mit­ment to pa­tients and is aligned with our strat­e­gy of build­ing the in­dus­try’s most com­pre­hen­sive fran­chise in DMD,” stat­ed Ed­ward Kaye, Sarep­ta’s chief ex­ec­u­tive of­fi­cer.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN